How do hormones affect the hair cycle?
Hair follicles are exquisitely sensitive to circulating hormones, particularly androgens and estrogens. Understanding what each hormone does to the hair cycle makes the HRT picture clearer.
Estrogentends to be hair-protective. It prolongs the anagen (active growth) phase of the hair cycle and is thought to promote hair density. The dramatic hair loss many women experience after childbirth — when estrogen drops sharply — is a well-recognized example of estrogen’s role in supporting hair retention.
Androgens, particularly dihydrotestosterone (DHT), shorten the anagen phase in genetically susceptible follicles, progressively miniaturizing them. This is the mechanism behind androgenetic alopecia — the most common form of hair loss in both men and women. Women with female-pattern hair loss (FPHL) typically have genetically sensitized follicles that respond more strongly to circulating androgens.
Progesterone has a more complex relationship with hair. Natural (bioidentical) progesterone has minimal androgenic activity. However, many synthetic progestogens — called progestins — are derived from testosterone and retain varying degrees of androgenic activity. That androgenic activity is the primary mechanism by which some progestins can worsen hair loss.
Which HRT formulations carry the most hair-loss risk?
Not all HRT is created equal. The type of progestogen used in a combined estrogen-progestogen regimen has the most direct bearing on hair effects.
| Progestogen | Androgenic activity | Hair-loss implication |
|---|---|---|
| Norethisterone (norethindrone) | High | Higher risk of worsening FPHL; avoid in androgen-sensitive women |
| Levonorgestrel | High | Androgenic; associated with increased FPHL risk |
| Tibolone | Moderate (androgenic + estrogenic) | Can worsen FPHL in susceptible women |
| Dydrogesterone | Low | Generally well tolerated in women with FPHL concerns |
| Micronized progesterone (bioidentical) | Minimal | Preferred choice for androgenetic alopecia; minimal hair risk |
| Drospirenone | Anti-androgenic | May benefit women with androgen-sensitive hair loss |
Two HRT regimens with the same estrogen can have opposite effects on hair — the progestogen is the variable that decides which.
HRT and hair loss from menopause: the estrogen decline factor
Menopause itself — independent of HRT — is a common trigger for hair thinning in women. The sharp drop in estrogen that accompanies the menopause transition removes a key protective signal from hair follicles, often revealing an underlying androgenetic tendency that estrogen had been offsetting.
In this context, estrogen-containing HRT can help stabilize or partially reverse the thinning. Several mechanisms may be involved: restoring the estrogen signal that prolongs the anagen phase, reducing the relative dominance of androgens, and improving general skin and follicle health through systemic estrogenic effects.
Improvement, when it occurs, is slow. Hair follicles cycle on a timescale of months. Most clinicians and dermatologists counsel patience — 6 to 12 months — before drawing conclusions about whether estrogen therapy is helping. This timeline is similar to that for other hair-loss treatments.
Does testosterone therapy cause hair loss in women?
Testosterone is increasingly used as part of hormone therapy in peri- and postmenopausal women, primarily for libido, energy, and mood. It is an FDA-approved medication when prescribed at physiologic doses for appropriate clinical indications.
Women with androgenetic alopecia or FPHL, or a strong family history of pattern hair loss, may be more susceptible to hair effects from exogenous testosterone. The mechanism is the same as in men: testosterone can be converted to DHT in scalp follicles by the enzyme 5-alpha reductase, and DHT is the primary androgen responsible for follicle miniaturization.
Dose matters significantly. Testosterone used in women is typically prescribed at a fraction of male doses, and when titrated carefully with lab monitoring, hair effects can often be minimized or avoided. Clinicians managing female hormone therapy typically monitor total and free testosterone levels — and sometimes SHBG and DHT — to keep androgen exposure in the physiologic range for women.
What is telogen effluvium, the temporary shedding after hormonal change?
Any significant hormonal shift — starting HRT, stopping HRT, or changing the type of HRT — can trigger a transient episode of diffuse hair shedding called telogen effluvium. This occurs because a large proportion of hairs simultaneously transition from the anagen (growth) phase to the telogen (resting/shedding) phase in response to the physiologic disruption.
Telogen effluvium typically begins 2–3 months after the trigger and resolves on its own within 3–6 months as the follicles resynchronize into their normal cycling pattern. It is not permanent hair loss in the usual sense — the follicles are not destroyed, they are just briefly synchronized into a shedding phase.
Distinguishing telogen effluvium from true androgenetic alopecia worsened by HRT is clinically important, because the management and prognosis differ. A dermatologist or clinician experienced in hair disorders can usually differentiate the two through examination and history.
What should you do if you notice hair changes on HRT?
If you notice increased hair shedding or thinning after starting or changing HRT, the first step is to contact your prescribing clinician. Do not stop HRT abruptly without discussing it — sudden cessation causes its own hormonal disruption.
Your clinician may:
- Review the progestogen in your regimen and switch to one with lower androgenic activity, such as micronized progesterone.
- Check androgen levels (testosterone, free testosterone, DHEA-S) to assess whether androgen excess is contributing.
- Assess thyroid function, ferritin, and B12, as deficiencies in these can independently cause or worsen hair loss and may coincide with the menopause transition.
- Refer to a dermatologist for scalp examination and, if indicated, a trichoscopy or biopsy to characterize the pattern.
- Discuss adjunctive options for androgenetic alopecia — such as topical minoxidil, which is FDA-approved and commonly used alongside hormone therapy.
A clinician-supervised HRT approach with regular labs and check-ins is the best way to catch and address these issues early, before significant progression occurs. If you’re exploring hormone therapy options with access to ongoing clinician oversight, you can start with a brief assessment here.
Frequently asked questions
Can HRT cause hair loss in women?
Yes, some forms of HRT can contribute to hair loss — particularly progestogens with androgenic activity (such as norethisterone or levonorgestrel) and testosterone-based formulations used in some peri/postmenopausal protocols. Estrogen, by contrast, typically supports hair retention. The net effect depends on which hormones are included, the dose, and individual androgen sensitivity.
Which type of HRT is most likely to cause hair loss?
Progestogens with androgenic properties carry the most hair-loss risk among commonly used HRT formulations. These include norethisterone (norethindrone), levonorgestrel, and tibolone. Bioidentical progesterone (micronized progesterone such as Prometrium or Utrogestan) has minimal androgenic activity and is generally better tolerated by women with androgenic alopecia. Estrogen therapy alone tends to support hair density.
Can HRT help hair loss from menopause?
In women whose hair loss is driven primarily by the estrogen decline of menopause, estrogen-containing HRT can help stabilize or partially reverse hair thinning. Estrogen prolongs the anagen (growth) phase of the hair cycle. Results are not universal, and improvement typically takes 6–12 months to become visible.
Does testosterone therapy cause hair loss in women?
Testosterone therapy — sometimes used for libido or energy in peri/postmenopausal women — can accelerate androgenetic alopecia in women who are genetically predisposed. Risk depends on dose and the extent to which testosterone converts to DHT (dihydrotestosterone) in scalp follicles. Monitoring testosterone and free DHT levels helps clinicians titrate to minimize hair effects.
What should I do if I notice hair loss after starting HRT?
Contact your prescribing clinician. Hair shedding in the first 1–3 months of a new HRT formulation can be a temporary adjustment (a "telogen effluvium") rather than a permanent effect. If shedding persists, your clinician may adjust the progestogen type or dose, switch to bioidentical progesterone, or investigate other contributing causes.